Training activity information
Details
Interpret and report pharmacogenetic testing in oncology patients, to include:
- DPYD
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What are the different DPYD genotypes and their associated phenotypes regarding enzyme activity and risk of fluoropyrimidine-related toxicity?
- What are the established guidelines for dose adjustment or alternative treatment strategies based on DPYD genotype?
- What are the key elements that should be included in a pharmacogenetic report for DPYD, ensuring clear guidance for clinicians on drug management?
- How will you develop your skills in interpreting DPYD results and formulating appropriate recommendations for treatment?
- Will you review example DPYD pharmacogenetic reports with your training officer or a clinical pharmacist?
- What resources (e.g., relevant pharmacogenetic databases, clinical guidelines) will you consult to prepare for interpretation and reporting?
- What potential challenges might you anticipate in interpreting and reporting DPYD results (e.g., complex genotype combinations, unclear genotype-phenotype correlations)? How might you approach these?
In action
- How are you currently approaching the interpretation and reporting of DPYD results, and what real-time decisions are you making to synthesise genotype, predicted phenotype, and chemotherapy regimens into clear, actionable dosing recommendations?
- What challenges are you encountering in this moment—such as managing complex genotypes or potential drug interactions—and how effectively can you translate these findings to improve treatment outcomes and prevent adverse drug reactions?
- How are you ensuring your findings align with current guidelines, and what specialist resources or clinical input (e.g., from a pharmacist) are you utilising right now to resolve ambiguity for genotypes not clearly defined in standard protocols?
On action
- How did you present the DPYD genotype and predicted phenotype in your reports?
- How did you incorporate relevant clinical guidelines or recommendations into your interpretation?
- Were there any challenges in communicating the implications of the DPYD results for treatment management?
- Did you enhance your skills in interpreting and reporting pharmacogenetic test results, specifically for DPYD?
- Did you learn about the importance of clear and actionable recommendations in pharmacogenetic reports?
- How do you ensure that pharmacogenetic results are integrated into the patient’s electronic health record and used to guide prescribing?
- What resources will you use to support your interpretation and reporting of pharmacogenetic tests?
- How will you ensure that your reports are aligned with current clinical best practices?
- How will you contribute to educating clinicians about the appropriate use and interpretation of pharmacogenetic testing?
Beyond action
- Reflecting on your initial experiences interpreting and reporting pharmacogenetic results in oncology, particularly for DPYD, how has your understanding of the clinical recommendations associated with different genotypes deepened?
- Have you encountered situations where the pharmacogenetic report directly influenced prescribing decisions? How did this real-world impact compare to your initial expectations?
- How have the interpretation and reporting skills developed here been applicable to other pharmacogenetic markers or in different therapeutic areas?
- As the clinical implementation of pharmacogenomics expands, how will your foundational skills enable you to effectively communicate this information to guide personalised treatment strategies in the future?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 6 |
Outcome
Analyse, interpret and report pharmacogenetic testing in oncology patients. |